Liquidia (NASDAQ:LQDA) Director Raman Singh Sells 9,024 Shares

Liquidia Corporation (NASDAQ:LQDA) Director Raman Singh sold 9,024 shares of the stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $68.62, for a total value of $619,226.88. Following the sale, the director owned 44,637 shares in the company, valued at $3,062,990.94. The trade was a 16.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Raman Singh also recently made the following trade(s):

• On Monday, September 14th, Raman Singh sold 8,468 shares of Liquidia stock. The stock was sold at an average price of $66.16, for a total value of $560,242.88.

Liquidia Stock Performance

NASDAQ:LQDA traded up $0.41 during midday trading on Tuesday, reaching $65.72. 1,372,017 shares of the company traded hands, compared to its average volume of 1,724,839. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. Liquidia Corporation has a twelve month low of $21.15 and a twelve month high of $93.61. The company has a fifty day moving average price of $77.19 and a 200 day moving average price of $59.67. The firm has a market capitalization of $5.88 billion, a price-to-earnings ratio of 47.97 and a beta of 0.53.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. During the same quarter last year, the company posted ($0.49) EPS. Liquidia’s revenue for the quarter was up 1842.1% on a year-over-year basis. On average, analysts expect that Liquidia Corporation will post 2.57 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have issued reports on LQDA shares. Needham & Company LLC boosted their price target on Liquidia from $70.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Lifesci Capital lowered Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price target on the stock. in a report on Wednesday, August 12th. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday. Bank of America upped their price objective on shares of Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a report on Thursday, August 13th. Finally, BTIG Research upped their price objective on shares of Liquidia from $109.00 to $111.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $98.08.

Institutional Investors Weigh In On Liquidia

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp purchased a new stake in Liquidia in the 2nd quarter worth about $29,694,000. Bank of America Corp DE grew its stake in Liquidia by 18.7% during the 1st quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after acquiring an additional 360,372 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in Liquidia during the 1st quarter valued at about $9,337,000. T3 Companies LLC acquired a new position in shares of Liquidia in the 4th quarter valued at about $6,084,000. Finally, Eversept Partners LP increased its holdings in shares of Liquidia by 33.0% in the 1st quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares during the period. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious cardiopulmonary conditions, including pulmonary arterial hypertension (PAH). The company is headquartered in Research Triangle Park, North Carolina, and serves healthcare providers and patients primarily in the United States.

Liquidia’s lead product is Yutrepia, an inhaled formulation of treprostinil designed for the treatment of PAH. The company has also developed treprostinil injection products and is pursuing additional therapies for rare cardiopulmonary diseases.